Prostaglandin Market: Current Analysis and Forecast (2022-2030)

Prostaglandins are hormone-like substances that play a crucial role in several physiological processes such as inflammation, pain, and blood clotting. These compounds are produced naturally by the body and are also available in synthetic forms for therapeutic use. The increasing prevalence of chronic diseases such as arthritis, cancer, and cardiovascular diseases, which require the use of prostaglandin-based medications is the important factor driving the growth of the prostaglandin market. For instance, as per the Rheumatoid Arthritis Network, in 2021, around 350 million people are living with arthritis globally.

Prostaglandin Market is expected to grow at a strong CAGR of 8% during the forecast period owing to increasing research efforts on the prostaglandin drug. For instance, the Federal University of Rio Grande do Sul conducted to compare the efficacy of topical application of PSLT and prostaglandin-like antihypertensive eye drops in the treatment of patients with ocular hypertension or glaucoma to reduce intraocular pressure and to reduce intraocular pressure using computerized perimetry and light therapy.

Based on type, the market is segmented into synthetic and natural. As per our analysis, the synthetic segment acquired a major share in 2021. Synthetic prostaglandins are typically used in the treatment of a variety of conditions, including ulcers, glaucoma, and erectile dysfunction. Synthetic prostaglandin can be produced in large quantities which is an important factor for the large share of the prostaglandin segment.

Based on the category, the market is segmented into human and veterinary. The veterinary segment is expected to grow with a higher CAGR in the prostaglandin market during the forecast period. The rising adoption of pets and livestock animals, along with the increasing prevalence of chronic disease among them is the major reason driving the growth of the veterinary segment.

Based on application, the market is segmented into cardiovascular, gynecological and obstetrical, ophthalmologic, and others. As per our analysis, the cardiovascular segment acquired a major share in 2021. The increasing prevalence of cardiac diseases is the main reason for the large share of cardiovascular diseases in the prostaglandin market. For instance, as per the World Health Organization (WHO), Cardiovascular disease (CVD) is the leading cause of death worldwide, claiming an estimated 17.9 million lives each year.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North American region held the dominant share of the prostaglandin market in 2021. This is mainly due to the presence of major economies such as the U.S., along with the presence of a large geriatric population in the region are the important factors for the market growth of the prostaglandin market in the region. For instance, as per the Administration for Community Living, In 2019, there were 54.1 million people aged 65 and over, including 30 million women and 24.1 million men in the U.S.

Some of the major players operating in the market include: Sanofi.; Cayman Chemical; YONSUNG Fine Chemicals Co.; Johnson Matthey; Chirogate International Inc.; Everlight Chemical Industrial Co.; Merck KGaA; Zhejiang Ausun Pharmaceutical Co., Ltd.; AspenBio; and Pfizer Inc.